Viktor Grünwald, MD, PhD, University Hospital Essen, describes the CheckMate 914 Part B analysis, the inspiration to investigate adjuvant nivolumab monotherapy for patients with localized RCC at high risk of relapse after nephrectomy, and what he believes to be on the horizon for immunotherapy research in the RCC adjuvant setting.
CheckMate 914 Part B: Nivolumab Monotherapy for Localized RCC After Nephrectomy
By Viktor Grünwald, MD, PhD - Last Updated: January 30, 2024Related Posts
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.